| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 2.8K | 2.5% | 10.6% |
| Total Income | 2.8K | 2.5% | 10.6% |
| Expenditure | 2.8K | 8.1% | 42.3% |
| PBT | -9.00 | 106.8% | 101.6% |
| Net Profit | -20.60 | 121.1% | 104.4% |
| OPM | — | ||
| NPM | -0.73% | 4.30pp | 19.14pp |
| EPS | -0.14 | 121.2% | 104.4% |
Biogen Reports Q3 2026 Results with 11% Revenue Growth
28 Oct 2026 · 28 Oct, 3:41 pm
Summary
Biogen announced third quarter 2026 financial results, with total revenue increasing 11% year-over-year to $2.8 billion. This growth was significantly boosted by the Growth Portfolio, which saw a 49% increase driven by acquired Apellis products. While GAAP diluted EPS was $(0.14) due to transaction costs, Non-GAAP diluted EPS stood at $2.62. The company raised its full-year 2026 Non-GAAP diluted EPS guidance, reflecting ongoing business strength and favorable Apellis dilution. Management highlighted the return to growth and the strength of the Growth Portfolio.
Key Highlights
- 1
Biogen reported third quarter 2026 total revenue of $2.8 billion, an increase of 11% year-over-year.
- 2
Growth Portfolio revenue reached $1.26 billion, up 49% year-over-year, driven by a strong contribution from acquired Apellis products.
- 3
GAAP diluted EPS was $(0.14) due to transaction-related charges, while Non-GAAP diluted EPS was $2.62.
- 4
The company is raising the lower end of its full year 2026 Non-GAAP diluted EPS guidance to $12.20 to $13.00.
- 5
Third quarter results reflect strong operating performance from the legacy Apellis portfolio following successful integration.
- 6
Total revenue for the nine months ended September 30, 2026, was $8.018 billion, an increase of 5.3% year-over-year.
Management Comments
Christopher A. Viehbacher
Our third quarter results demonstrate that Biogen has returned to growth. We’re seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products. With multiple Phase 3 readouts expected over the next 12 months, we are positioned to further strengthen our long-term growth profile and create sustainable value for patients and shareholders.
Informational and educational content only. Not investment advice.